Engineer, MES, Devens Biologics Digital Plant at Bristol-Myers Squibb

Devens, Massachusetts, United States

Apply Now

Not SpecifiedCompensation

Junior (1 to 2 years)Experience Level

Full TimeJob Type

UnknownVisa

Biopharmaceuticals, ManufacturingIndustries

Requirements

BS in Engineering, Computer Science, or its equivalent
Minimum 2 years of experience preferably in the Pharmaceutical or Biotechnology sector
Minimum 2 years of Manufacturing Execution Systems software design experience in batch operation following ISA 88/ISA95 standard
Experience with Manufacturing Execution System software (preferably Syncade) in a manufacturing environment
Good written and verbal communication skills
Good interpersonal skills and the ability to work in a team environment
Ability to work with minimal supervision

Responsibilities

Support the operation of all GMP manufacturing systems (Manufacturing Execution System) in the Manufacturing facilities in Devens, MA
Provide troubleshooting support and guidance of Manufacturing Execution Systems in support of Manufacturing
Investigate the root cause of MES problems and propose solutions to prevent recurrence
Lead or manage Manufacturing Execution Systems small size projects
Support the configuration, testing and implementation of process control solutions to a variety of complex technical problems
Ensure the documentation of the knowledge base on how to resolve issues encountered, thus facilitate the job for future activities

Skills

MES

Manufacturing Execution System

GMP

GxP

recipe authoring

troubleshooting

root cause analysis

process control

configuration

testing

implementation

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

New York City, New YorkHeadquarters

1887Year Founded

$33,706.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.

BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.

Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.

The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.

BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.

The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.

BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI

Try Jobo Free